Rethink Breast Cancer, a registered Canadian charity, is raising awareness and funding for the Canadian research arm (Baby Time) of the international POSITIVE clinical trial to understand and overcome the challenges some women face when trying to get pregnant after cancer. The trial will evaluate the pregnancy outcomes and safety of interrupting endocrine therapy for young women with ER+ breast cancer who desire pregnancy.
Drugs administered during cancer treatment and in the adjuvant setting can have adverse effects on a woman’s reproductive system. The study will investigate what will happen if young women take a break in their hormonal treatment to try to conceive naturally.
Most hormone-responsive breast cancer patients follow up adjuvant treatment with 5 to 10 years of endocrine therapy to reduce the chances of recurrence. While chemotherapy can put young women into early menopause, limiting their fertility, endocrine therapy can impact the ovaries as well as carry associated risks to a growing fetus.
Research associated with the risk of pregnancy after breast cancer is limited. The study will provide oncologists and other physicians data to be able to inform a woman about the possible risks.
More than 60 breast cancer centres in 20 countries are participating in the international study, and Rethink has committed to funding the Canadian research arm, led by Dr Karen Gelmon, co-chair of the NCIC Clinical Trials Group Breast Site Committee and medical oncologist with the Department of Medical Oncology, BC Cancer Agency.
Rethink Breast Cancer has committed to raising $100 000 to cover the costs of each patient entered into the study over 4 years (each patient will be followed for up to 10 years) and has launched a crowdfunding campaign to raise the initial $15 000 required to enter the first patients into the study in 2015. To learn more about the study, visit rethinkbreastcancer.com.
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org